BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. European Journal of Pharmacology 2015;746:258-66. [DOI: 10.1016/j.ejphar.2014.11.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271-289. [PMID: 28851502 DOI: 10.1016/j.ejmech.2017.07.062] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 15.2] [Reference Citation Analysis]
2 Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo RG, Kolenko VM. Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. Mol Cancer Ther 2018;17:1355-64. [PMID: 29967214 DOI: 10.1158/1535-7163.MCT-17-1299] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 18.0] [Reference Citation Analysis]
3 Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet 2017;56:825-92. [PMID: 28210973 DOI: 10.1007/s40262-017-0506-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 21.0] [Reference Citation Analysis]
4 Alves R, Gonçalves AC, Jorge J, Almeida AM, Sarmento-ribeiro AB. Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia. Biomedicines 2022;10:1158. [DOI: 10.3390/biomedicines10051158] [Reference Citation Analysis]
5 Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. Eur J Drug Metab Pharmacokinet 2017;42:915-33. [PMID: 28374336 DOI: 10.1007/s13318-017-0411-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
6 Abdel-Aziz AK, Abdel-Naim AB, Shouman S, Minucci S, Elgendy M. From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib. Front Pharmacol 2017;8:718. [PMID: 29066973 DOI: 10.3389/fphar.2017.00718] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance. Front Pharmacol 2021;12:648407. [PMID: 33953682 DOI: 10.3389/fphar.2021.648407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Lv Y, Wang H, Li G, Zhao B. Three-dimensional decellularized tumor extracellular matrices with different stiffness as bioengineered tumor scaffolds. Bioact Mater 2021;6:2767-82. [PMID: 33665508 DOI: 10.1016/j.bioactmat.2021.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wu CP, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, Hung TH, Wu YS. Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Cancers (Basel) 2020;12:E195. [PMID: 31941029 DOI: 10.3390/cancers12010195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Ma Y, Wang B, Guo Y, Zhang Y, Huang S, Bao X, Bai M. Inhibition of miR-196a affects esophageal cancer cell growth in vitro. Biomedicine & Pharmacotherapy 2016;84:22-7. [DOI: 10.1016/j.biopha.2016.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Peng X, Li L, Ren Y, Xue H, Liu J, Wen S, Chen J. Synthesis of N ‐Carbonyl Acridanes as Highly Potent Inhibitors of Tubulin Polymerization via One‐Pot Copper‐Catalyzed Dual Arylation of Nitriles with Cyclic Diphenyl Iodoniums. Adv Synth Catal 2020;362:2030-8. [DOI: 10.1002/adsc.201901460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Ballesteros PÁ, Chamorro J, Román-Gil MS, Pozas J, Gómez Dos Santos V, Granados ÁR, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:5981. [PMID: 34885091 DOI: 10.3390/cancers13235981] [Reference Citation Analysis]
13 Wang H, Luo F, Zhu Z, Xu Z, Huang X, Ma R, He H, Zhu Y, Shao K, Zhao J. ABCG2 is a potential prognostic marker of overall survival in patients with clear cell renal cell carcinoma. BMC Cancer 2017;17:222. [PMID: 28347288 DOI: 10.1186/s12885-017-3224-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y. Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics. Front Oncol 2019;9:1302. [PMID: 31921617 DOI: 10.3389/fonc.2019.01302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Xu L, Huang J, Liu J, Xi Y, Zheng Z, To KKW, Chen Z, Wang F, Zhang Y, Fu L. CM082 Enhances the Efficacy of Chemotherapeutic Drugs by Inhibiting the Drug Efflux Function of ABCG2. Mol Ther Oncolytics 2020;16:100-10. [PMID: 32055675 DOI: 10.1016/j.omto.2019.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ben Cheikh Y, Xuereb B, Boulangé-Lecomte C, Le Foll F. Multixenobiotic resistance in Mytilus edulis: Molecular and functional characterization of an ABCG2- type transporter in hemocytes and gills. Aquat Toxicol 2018;195:88-96. [PMID: 29304406 DOI: 10.1016/j.aquatox.2017.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Nazari-vanani R, Azarpira N, Heli H, Karimian K, Sattarahmady N. A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. Colloids and Surfaces B: Biointerfaces 2017;160:65-72. [DOI: 10.1016/j.colsurfb.2017.09.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
18 Wu CP, Hung TH, Hsiao SH, Huang YH, Hung LC, Yu YJ, Chang YT, Wang SP, Wu YS. Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. Cancers (Basel) 2020;12:E1366. [PMID: 32466597 DOI: 10.3390/cancers12061366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Karbownik A, Sobańska K, Płotek W, Grabowski T, Klupczynska A, Plewa S, Grześkowiak E, Szałek E. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Invest New Drugs 2020;38:574-83. [PMID: 31177402 DOI: 10.1007/s10637-019-00806-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Mol Pharm 2019;16:3040-52. [PMID: 31117741 DOI: 10.1021/acs.molpharmaceut.9b00274] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
21 Yu DH, Liu YR, Luan X, Liu HJ, Gao YG, Wu H, Fang C, Chen HZ. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance. Bioconjug Chem 2015;26:1702-12. [PMID: 26076081 DOI: 10.1021/acs.bioconjchem.5b00283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]